Some people might question why now, but if a company wants to get approval for a trial it needs to show it has the funds to complete it.
Column 1 1 Proceeds from the Placement will be used to:- fund further clinical development of OPT-302 as a therapy for wet Age-related Macular Degeneration (“wet AMD” or “wAMD” through commencement of two concurrent Phase 3 pivotal registrational trials in approximately 660 wet AMD patients each; and- manufacture sufficient quantities of clinical grade OPT-302 for Phase 3 clinical development
Ann: Opthea Raises A$50 million in Institutional Placement, page-3
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
81.5¢ |
Change
0.030(3.82%) |
Mkt cap ! $1.003B | |||
| Open | High | Low | Value | Volume |
| 78.5¢ | 82.5¢ | 78.5¢ | $1.203M | 1.499M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5772 | 81.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 82.5¢ | 844 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| OPT (ASX) Chart |